These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 11999351)

  • 21. Angiogenesis in multiple myeloma.
    Rajkumar SV; Kyle RA
    Semin Oncol; 2001 Dec; 28(6):560-4. PubMed ID: 11740809
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical importance of angiogenesis and angiogenic factors in oncohematology].
    Grosicki S; Grosicka A; HoĊ‚owiecki J
    Wiad Lek; 2007; 60(1-2):39-46. PubMed ID: 17607967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiogenesis and vasculogenesis in multiple myeloma: role of inflammatory cells.
    Vacca A; Ribatti D
    Recent Results Cancer Res; 2011; 183():87-95. PubMed ID: 21509681
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytokines as anti-angiogenic agents in haematological malignancies.
    Cocco C; Ferretti E; Airoldi I; Pistoia V
    Curr Cancer Drug Targets; 2011 Nov; 11(9):997-1004. PubMed ID: 21933108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies.
    Giles FJ
    Oncologist; 2001; 6 Suppl 5():32-9. PubMed ID: 11700390
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
    Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
    Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Lenalidomide in hematological malignancies---review].
    Jin X; Zhang YZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Feb; 20(1):205-9. PubMed ID: 22391198
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiogenesis and hematological malignancies.
    Lim ST; Levine AM
    Hematology; 2005 Feb; 10(1):11-24. PubMed ID: 16019441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiogenesis and anti-angiogenesis in hematological malignancies.
    Ribatti D; Vacca A; Dammacco F; English D
    J Hematother Stem Cell Res; 2003 Feb; 12(1):11-22. PubMed ID: 12662432
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is angiogenesis essential for the progression of hematological malignancies or is it an epiphenomenon?
    Ribatti D
    Leukemia; 2009 Mar; 23(3):433-4. PubMed ID: 19277048
    [No Abstract]   [Full Text] [Related]  

  • 31. Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors.
    Negaard HF; Iversen N; Bowitz-Lothe IM; Sandset PM; Steinsvik B; Ostenstad B; Iversen PO
    Leukemia; 2009 Jan; 23(1):162-9. PubMed ID: 18800145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of hematopoietic growth factors in angiogenesis.
    Ribatti D; Vacca A; De Falco G; Ria R; Roncali L; Dammacco F
    Acta Haematol; 2001; 106(4):157-61. PubMed ID: 11815712
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Quantification and morphometric analysis of vascular structures in the bone marrow. A critical review].
    Kvasnicka HM; Thiele J
    Pathologe; 2002 Nov; 23(6):472-9. PubMed ID: 12436301
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High heparanase activity in multiple myeloma is associated with elevated microvessel density.
    Kelly T; Miao HQ; Yang Y; Navarro E; Kussie P; Huang Y; MacLeod V; Casciano J; Joseph L; Zhan F; Zangari M; Barlogie B; Shaughnessy J; Sanderson RD
    Cancer Res; 2003 Dec; 63(24):8749-56. PubMed ID: 14695190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiangiogenic therapy in leukemia.
    Thomas DA; Giles FJ; Cortes J; Albitar M; Kantarjian HM
    Acta Haematol; 2001; 106(4):190-207. PubMed ID: 11815717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of angiogenesis in hematologic malignancies.
    Stasi R; Amadori S
    J Hematother Stem Cell Res; 2002 Feb; 11(1):49-68. PubMed ID: 11847003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome.
    Mileshkin L; Honemann D; Gambell P; Trivett M; Hayakawa Y; Smyth M; Beshay V; Ritchie D; Simmons P; Milner AD; Zeldis JB; Prince HM
    Haematologica; 2007 Aug; 92(8):1075-82. PubMed ID: 17640854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone marrow angiogenesis in multiple myeloma: effect of therapy.
    Kumar S; Fonseca R; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Gertz MA; Kyle RA; Greipp PR; Rajkumar SV
    Br J Haematol; 2002 Dec; 119(3):665-71. PubMed ID: 12437642
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proteasome inhibitors and modulators of angiogenesis in multiple myeloma.
    Ferrarini M; Ferrero E
    Curr Med Chem; 2011; 18(34):5185-95. PubMed ID: 22087819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Angiogenesis in malignant blood diseases].
    Ellegaard J; Nielsen JL
    Ugeskr Laeger; 1999 Jun; 161(26):4012. PubMed ID: 10402940
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.